

Bibliography

Adriana Sakalova et al. **(2006)** Multiple myeloma and paraproteinemias. *SAP*. 65-85.

Aglund k, Rauvala M, Puistola U, Angstrom T, Turpeenniemi HT, Zackrisson B, Stendahl U. **(2004)** Gelatinase A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. *Gynecol-Oncol*. 94(3):600-704.

Alaoui-Jamali MA, Ying-jie XU. **(2006)** Proteomic technology for biomarker profiling in cancer: an update. *J Zhejiang Univ SCIENCE B*. 7(6): 411-420.

Alessandro R, Fontana S, Kohn E, De Leo G.**(2005)** Proteomics strategies and their application in cancer research. *Tumori*. 91:447-455.

Aljada IS, Ramnath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D. **(2004)** Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. *J Clin Oncol*. 22: 3218–3229.

Anderson AJ. **(1965)** Factors affecting the amount and composition of the Serum Seromucoid Fraction. *Nature*.1965; 208: 491 – 492.

Annual report of population based and hospital based cancer registry of The Gujarat cancer and research institute report, **(2004)**.

Aranganathan S, Senthil K, Nalini N. **(2005)** A case control study of glycoprotein status in ovarian carcinoma. *Clin Biochem*. 38: 535-539.

Aurer I, Lauc G, Dumic J, Rendic D, Matisic D, Milos M, Heffer-Lauc M, Flogel M, Labar B. **(2007)** Aberrant glycosylation of IgG heavy chain in multiple myeloma. *Coll Antropol*. Mar; 31(1):247-251.

Avet-Loiseau H, Gerson F, Magrangeas F et al. **(2001a)** Rearrangements of the c-myc oncogenes are present in 15% of primary human multiple myeloma tumors. *Blood*. 98:3082-3086.

Avet-Loiuseau H, Daviet A, Sauner S et al. **(2000)** Chromosomes 13 abnormalities in multiple myeloma are mostly monosomy 13. *British Jn. Haematol*. 111:1116-1117.

Avet-Loiuseau H, Facon T, Daviet A et al. **(1999)** 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis in multiple myeloma. Intergrroupe Francophone du Myelome. *Cancer Research*. 59:4546-4550.

Avet-Loiuseau H. **(2001b)** Nonrandom distribution of chromosomal abnormalities and correlation with clinical stage and prognostic presentation: a novel model for oncogenesis in multiple myeloma. Program and abstracts of the VIII International Myeloma Workshop, Banff, Alta., Canada, 4-8 May, (Abstr.S5)

Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK et al (2005) Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. *Gynecologic Oncology*. 99: 26-35.

Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M. (1997) Metalloproteinases in multiple myeloma. Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2 and induction of MMP-1 by myeloma cells. *Blood*. 90(4) August 15:1649-1655.

Basoglu M, Atamanalp SS, Yildiran MI, Aydinli B, Ozturk G, Akcay F, Oren D. (2007) Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. *Eur Surg Res*. 39(3):136-140.

Bathi RJ, Nandimath K, Kannan N, Shetty P. (2001) Evaluation of glycoproteins as prognosticators in head and neck malignancy. *Indian J Dental Res*. Apr-Jun; 12(2): 93-99.

Becker DJ, John B. Lowe. (2003) Fucose: biosynthesis and biological function in mammals. *Glycobiology*. 13(7) 41R-53R, Review Oxford University Press.

Bergsagel PL, Kuehl WM. (2001) Chromosome translocations in multiple myeloma. *Oncogene*. 20: 5611-22.

Bode W and Maskos K. (2003) Review-Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases. *Biol. Chem*. June; 384:863-872.

Brew K, Dinakarbandian D, Nagase H. (2000) Tissue inhibitors of metalloproteinases: evolution, structure and function. *Biochim Biophys Acta*. 1477:267-283.

Brichory F, Beer D, Naour FL, Giordano T, Hanash S. (2001) Proteomics based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. *Cancer Research*. 61: 7908-7912.

Brinckerhoff CE and Matrisian LM. (2002) Matrix metalloproteinases: a tail of a frog that became a prince. *Nature Rev. Mol. Biol*. 3:207-214.

Catlett-Falcone R, Landowski TH, Oshiro MM et al. (1999) Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. *Immunity*.10:105-115.

Chakravarty PK, Ghosh A, Roychowdhury J. (1994) Effect of fibrosarcoma induction on copper and ceruloplasmin concentration in different organs of the host. *Neoplasma*. 41:187-189.

Charokopos N, Leotsinidis M, Tsiamita M, Kalofonos HP, Vasillakos P, Christofidou M, Spiropoulos K. (2004) Increased levels of albumin in bronchial washing fluid of patients with bronchial carcinoma. Could albumin

be considered as a tumor marker? *Int. J. Biol Markers*. Oct-Dec; 19(4):316-321.

Chesi M, Bergsagel PL, Shonukan OO et al. (1998a) Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. *Blood*. 91:4457-4463.

Chesi M, Brents LA, Ly SA et al (2001) Activate fibroblast growth factor-3 is oncogenes that contributes to tumor progression in multiple myeloma. *Blood*. 97:729-736.

Chesi M, Nardini E, Lim RS et al. (1998b) The t(4; 14) translocations in myeloma dysregulates both FGFR3 and novel gene, MNSET, resulting in IgH/HMSET hybrid transcripts. *Blood*. 92:3025-34.

Cylwik B, Chrostek L, Szmitkowski M. (2005) Diagnostic value of total and lipid bound sialic acid in malignancies. *Pol Merkur Lekarski*. Aug; 19(110):237-241.

Cylwik B, Chrostek L, Zalewski B, Dabrowski A, Szmitkowski M. (2007) Serum total sialic acid in differential diagnostics of jaundice caused by malignant and nonmalignant diseases: a ROC curve analysis. *Dig Dis Sci*. Sep; 52(9):2317-2322.

Dabelsteen E. (1996) Cell surface carbohydrates as prognostic markers in human carcinomas. *J. Pathol*. 179:358-369.

de Hingh IH, Wass ET, Lomme RM, Wobbes T, Hendriks T. (2004) Circulating matrix metalloproteinase-9 in transiently elevated after colorectal surgery. *Int. J. Colorectal Dis*. 19(5):446-450.

Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. (1993) Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. *Pharmacol Ther*. 59: 329–341.

Devita VT Jr, Hellman S, Rosenberg SA et al. (2001a) Plasma cell neoplasms 6th(ed). Lippincott Williams and Wilkins. Cancer, principles and practice of oncology. pp: 2465-2491.

Devita VT Jr, Hellman S, Rosenberg SA et al. (2001b) Gynecologic cancers. 6th(ed). Lippincott Williams and Wilkins. Cancer, principles and practice of oncology.; pp: 1519-1548.

Dragutinovic VV, Radovanovic NS, Izrael-Zivkovi LT, Vrvic MM. (2006) Detection of gelatinase B activity in serum of gastric cancer Patients. *World J Gastroenterol*. January 7; 12(1): 105-109.

Dwek MV and Alaiya AA. (2003) Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. *British Journal of Cancer*. 89: 305-307.

- Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD. (1996) Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). *Cancer Res.* 56: 2815–2822.
- Egeblad M, Werb Z. (2002) New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer.* 2: 161-174.
- Fairbanks G, Steck TL, Wallach DF. (1971) Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. *Biochemistry.* 10:2606-2617.
- Feijoo-Carnero C, Rodriguez-Berrocal FJ, Paez de la Cadena M, Ayude D, de Carlos A, Martinez-Zorzano VS. (2004) Clinical significance of preoperative serum sialic acid levels in colorectal cancer: utility in the detection of patients at high risk of tumor recurrence. *Int J Biol Markers.* Jan-Mar; 19(1):38-45.
- Fentress DS, Orrico LA, Kruspe M, Briscoe KS, Laber DA. (2006) Clinical review article on multiple myeloma. *Hospital Physician.* 15-25.
- Fernandez-Rodriguez J, Paez de la Cadena M, Martinez-Zorzano VS, Rodriguez-Berrocal FJ. (1997) Fucose levels in sera and in tumours of colorectal adenocarcinoma patients. *Cancer Lett.* Dec 23; 121(2):147-153.
- Frederick L, Greene et al (2002) (6thed). American joint committee on cancer (AJCC), Cancer Staging Hand Book.TNM Classification and Malignant Tumors. Springer, 293-298.
- Ge NL, Rudikoff S. (2000a) Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. *Oncogene.* 19:4091-4095.
- Ge NL, Rudikoff S. (2000b) Insulin-like growth factor I is a dual effector of multiple myeloma cells cell growth. *Blood.* 96:2856-2861.
- Geho DH, Petricoin EF, Liotta LA. (2004) Blasting into the microworld of tissue proteomics: A new window on cancer. *Clinical Cancer Research.* 10: 825-827.
- Geyer H, Geyer R. (2006) Strategies for analysis of glycoprotein glycosylation. *Biochimica et Biophysica Acta.* 1764:1853-1869.
- Gokmen SS, Kazezoglu C, Tabakoglu E, Altıay G, Gungor O, Ture M. (2004) Serum total sialic acid levels in lung cancer patients of different histological types with and no extrapulmonary metastases. *Turkish Journal of Biochemistry.* 29 (4): 262-267.
- Goldhirsch AE, Berger O, Muller R, Maibach S, Mitelis K, Buser et al. (1998) Ovarian cancer and tumor marker: sialic acid, galactosyl transferase and CA-125. *Oncology.* 45:281–286.
- Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. *Eur J Cell Biol.* 74: 111–122.

Goswami K, Nandeesh H, Koner BC, Nandakumar DN. (2007) A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis. *Prostate Cancer Prostatic Dis.*; Apr 3: [Epub ahead of print]

Gowda DC. (1984) Sialic acids: The unusual carbohydrates. *Science Reporter.* 114-120.

Gross J. and Lapiere CM. (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. *Proc. Natl. Acad. Sci. USA.* 48:1014-1022.

Hanamura I, Iida S, Akano Y et al. (2001) Ectopic expression of MAFB gene in human myeloma cells carrying (14;20) (q32;q11) chromosomal translocations. *Jpn J Cancer Research.* 92:638-644.

Harlow E. and Lane D. (1999) Using antibodies: A laboratory manual. Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York.

Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. (1992) Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. *FEBS Lett.* 298: 29-32.

Herzog A, Kuntz S, Hannelore D, Wenzel U et al. (2004) Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. *Int. J. Cancer.* 109: 220-229.

Hideshima T, Nakamura N, Chauhan D et al. (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. *Oncogene.* 20:5991-6000.

Hoekstra R, Eskens FALM, Verweij J. (2001) Matrix metalloproteinase inhibitors: current developments and future perspectives. *The oncologist.* 6: 415-427.

Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brunner N, Fernebro E. (2004) Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. *Eur J Cancer.* 40: 64-72.

Holten-Andersen MN, Brunner N, Christensen IJ, Jensen V, Nielsen HJ. (2002) Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components. *Scand J Clin Lab Invest.* 62: 223-230.

Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer Hansen G et al. (1999) Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. *Br J Cancer.* 80(3-4): 495-503.

Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. (2000) High preoperative plasma tissue inhibitor

of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. *Clin Cancer Res.* 6(11): 4292-4299.

Huang LW, Garrett AP, Bell DA et al. (2000) Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. *Gynecol Oncol.* 77:369-376.

Huang ZY, Xiong G, Zhang J, Wang WJ. (2007) Screening of differentially expressed proteins from human esophageal cancer and esophageal tissues by two-dimensional difference gel electrophoresis and mass spectrometry. *Nan Fang Yi Ke Da Xue Xue Bao.* 27(9):1406-1409. [Article in Chinese]

Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, Kang KR, Hyun JS, Chung KH. (2005) Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. *J Korean Med Sci.* 20:450-455.

Iki K, Takeo T, Kubozoe T, Aoki S, Hayashi J, Tsunoda T. (2002) Detection of serum MMPs in tumor-bearing hamsters. *J Hepatobiliary Pancreat Surg.* 9(4):478-84.

Indraccolo S, Favaro E, Amadori A. (2006) Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. *Cell Cycle.* 5(16):1751-1755.

Ivanova M, Tzvetanova E, Jetcheva V, Kilar F. (2002) Abnormal protein patterns in blood serum and cerebrospinal fluid detected by capillary electrophoresis. *J. Biochem. Biophys Methods.* Oct-Nov; 53(1-3):141-150.

Jiang Y, Goldberg ID, Shi IE. (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. *Oncogene.* 21: 2245-2252.

Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M, Matache C. (2006) MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. *J Cell Mol Med.* 10: 499-510.

John A, Tuszynski G. (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. *Pathology oncology research.* 7(1):14-23.

Johnson PWM, Whelan J, Longhurst S, Stepniewska K, Matthews J, Amess J, Norton A, Rohatiner AZS, Lister TA. (1993) β -2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. *Br.J.Cancer.* 67:792-797.

Kanoh Y, Ohtani N, Mashiko T, Ohtani S, Nishikawa T, Egawa S, Baba S, Ohtani H. (2001) Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer. *Anticancer Res.* Jan-Feb; 21(1B):551-556.

Kavallaris M and Marshall GM. (2005) From Bench to Bedside-Proteomics and disease: opportunities and challenges. *MJA.* 182(11):575-579.

Kopczynska E, Dancewicz M, Kowalewski J, Kardymowicz H, Tyrakowski T. (2007) The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients. *Pol Merkur Lekarski*. Jun; 22(132):539-541.

Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. (1993) Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. *Oncol Res*. 5: 19–28.

Kossowska B, Ferens-Sieczkowska M, Gancarz R, Passowicz-Muszyiska E, Jankowska R. (2005) Fucosylation of serum glycoproteins in lung cancer patients. *Clin Chem Lab Med*. 43(4):361-369.

Krecicki T, Leluk M. (1992) Acute phase reactant proteins an aid to monitoring surgical treatment of laryngeal carcinoma. *J.Laryngol.Otol*.106:613-615.

Krzyslak A, Gaj Z, Pomorski L, Lipinska A. (2007) Sialylation of intracellular proteins of thyroid lesions. *Oncol Rep*. May; 17(5):1237-1242.

Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. (2003) Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas. *Eur J Haematol*. 71: 91–99.

Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. (2002) Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. *Eur J Haematol*. 69: 205–212.

Kulkarni MS, Daggett JL, Bender TP et al. (2002) Frequent inactivation of the cyclin dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. *Leukemia*. 16:127-134.

Kumar L, Vikram P, Kochupillai V. (2006) Recent advances in the management of multiple myeloma. *Natl Med J India*. 19 (2): 80-89.

Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. (2002) Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. *Anticancer Res*. 22: 2221–2227.

Kyle RA, Gertz MA, Witzig TE et al. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. *Mayo Clin Proc*. 78:21-33.

Lein M, Jung K, Laube C, Hubner T, Winkelmann B, Stephan C et al. (2000) Matrix metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. *Int J Cancer*. 85:801-804.

Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. **(2001)** Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. *Gynecologic Oncology*. August. (82)2:291-298.

Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. **(2005)** Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in colorectal carcinoma invasion and metastasis. *World J Gastroenterol*. 11(20):3046-3050.

Liang XH, Liang XM, Yi B. **(2003)** Determination of serum sialic acid in three kinds of malignant tumor and its clinical significance. *Hunan Yi Ke Da Xue Xue Bao*. Feb 28; 28(1):65-66.

Liebler DC and Yates JR. **(2002)** Introduction to proteomics: Tools for the new biology. (Humana press):25-109.

Liotta LA, Kohn EC. **(2001)** The microenvironment of the tumor-host interface. *Nature*. 411:375-379.

Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P et al. **(2007)** Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. *Cancer*. 109(10):1933-1939.

Listinsky JJ, Siegal GP, Listinsky CM. **(1998)** α -L Fucose- A potentially critical molecule in pathologic processes including neoplasia. *Am J Clin Pathol*. 110:425-440.

Lopata A, Agresta F, Quinn MA, Smith C, Ostor AG, Salamonsen LA. **(2003)** Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity. *Gynecologic Oncology*. August; 90(2):318-324.

Lorenzo JA, Pilbeam CC, Kalinowski JF, Hibbs MS. **(1992)** Production of both 92 and 72 KDa gelatinases by bone cells. *Matrix*. 12:282-290.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. **(1951)** Protein measurement with the Folin phenol reagent. *J Biol Chem*. 193: 265-275.

Mancini HS, Carbonara AO, Heremans JF. **(1965)** *Immunohistochemistry*. 2: 235.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R. **(2003)** Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. *Eur J Cancer*. 39: 1948-1956.

Martin NH, Franglen GT. **(1954)** Agarose gel electrophoresis. *J.Clin Pathol*. 7: 87.

- Masanori Ii, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. (2006) Role of matrixmetalloproteinase-7 (Matrilysin) in human cancer invasion, apoptosis, growth and angiogenesis. *Exp Biol Med.* 231:20-27.
- Meisser A, Cohen M, Bischof P. (2005) Concentration of circulating gelatinases are dependent on the condition of blood collection. *Clinical Chemistry.*51:274-276.
- MMPs (MMP-2, MMP-9) TIMPs (TIMP-1, TIMP-2) protocol followed by ELISA Kits (R & D Systems, USA).
- Mook ORF, Frederiks WM, Van Noorden CJF. (2004) The role of gelatinases in colorectal cancer progression and metastasis. *Biochim Biophys Acta.* 1705: 69-89.
- Moran A, Iniesta P, Garcia-Aranda C et al. (2005) Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. *Oncol Rep.* 13: 115-120.
- Mueller M, Martens L, Apweiler R. (2007) Annotating the human proteome: Beyond establishing a parts list. *Biochimica et Biophysica Acta.* 1774: 175-191.
- Mukhopadhyay T, Giri A, Dasgupta A. (2003) Evaluation of serum mucoproteins in patients suffering from liver cancers. *Indian Journal of Clinical Biochemistry.* 18(2):131-135.
- Murphy G. (1995) Matrixmetalloproteinases and their inhibitors. *Acta orthopedic scandinavica.* 266: 55-60
- Murray RK, Granner DK, Rodwell VW. (2006) Glycoprotein (27th ed) Haper'S illustrated Biochemistry, Lange medical books/McGraw-Hill. 523-544.
- Myron Johnson A, Merlini G, Sheldon J, Ichihara K. (2007) Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC): IFCC Scientific Division Committee on Plasma Proteins (C-PP). *Clin Chem Lab Med.* 45:419-426.
- Nagal Y et al. Tadpole collagenase. (1966) *Prepration and purification.Biochemistry.* 5:3123-3130.
- Nagase H, Woessner JF. (1999) Matrixmetalloproteinases. *J. Biol chem.* 274:21491-21494.
- Nagase H. (1997) Activation mechanisms of matrix metalloproteinases. *Biol Chem.* 378:151-160.
- Nair SA, Karunagaran D, Nair MB, Sudhakaran PR. (2003) Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. *J Cancer Res Clin Oncol.* 129:123-131.
- Nandave M, Ojha SK, Kaur R. (2005) Changes in levels of serum glycoproteins in major depressive disorders. *Indian Journal of Clinical Biochemistry.* 20(2):154-157.

National cancer control programme. (2008) Task force report for XIth plan, Ministry of health and family welfare, Govt of India. March. Load of major cancer in India, 2001:1-132.

National cancer registry programme. (2005) Two year report of the population based cancer registries 1999-2000. New Delhi: Indian Council of Medical Research.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. (2000) Matrix metalloproteinases: biologic activity and clinical implications. *J Clin Oncol.* 18: 1135–1149.

Neri A, Baldini L, Trecca D et al. (1993) p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. *Blood.* 81:128-135.

O' Farrell PH. (1975) High resolution two-dimensional electrophoresis of proteins. *J.Biol.Chem.* 250:4007-4021.

O'Connell TX, Horita TJ, Kasravi B. (2005) Understanding and interpreting serum protein electrophoresis. *American family Physician.* 71(1):105-112.

Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. (2000) Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. *Anticancer Res.* 20: 1085-1091.

Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E, Mohar-Betancourt A. (2007) Serum albumin as a significant prognostic factor for patients with gastric carcinoma. *Ann Surg Oncol.* Feb 14(2):381-389.

Orczyk-Pawilowicz M. (2007) The role of fucosylation of glycoconjugates in health and disease. *Postepy Hig Med Dosw* (Online). 61:240-52. [Article in Polish].

Overall CM. (2002) Molecular determinants of metalloproteinase substrate specificity: Matrix metalloproteinase substrate binding domains, modules, and exosites. *Mol. Biotech-nol.* 22:51-86.

Ozier O, Amin N, Ideker T. (2003) Global architecture of genetic interactions on the protein network. *Nat. Biotechnol.* 21(5):490-491.

Pan S, Zhang H, Rush J, et al. (2005) High throughput proteome screening for biomarker detection. *Mol Cell Proteomics.* 4:182-190.

Parkin DM, Bray F, Ferlay J, Pisani P. (2005) Global cancer statistics, 2002. *CA Cancer J Clin.* 55: 74-108.

Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, Patel PS. **(2005)** Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. *International Journal of Surgical Oncology*. 90: 81-88.

Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. **(2007)** Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. *Head Neck*. 29: 564-572.

Patel PS, Adhvaryu SG, Balar DB, Parikh BJ, Shah PM. **(1994)** Clinical application of serum levels of sialic acid, fucose and seromuroid fraction as tumour markers in human leukemias. *Anticancer Research*. 14: 747-752.

Patel PS, Mehta AA, Desai AA. **(2005a)** Techniques of cancer research in post-genomic era. *Amala Cancer Research Bulletin*. 25: 50-66.

Patel PS, Patel MM, Raval GN, Rawal RM, Balar DB, Patel DD. **(1998)** Seromuroid fraction: a useful biomarker for patients with breast cancer. *Am J Clin Oncol*. Jun; 21(3):258-262.

Patel PS, Raval GN, Patel MM, Balar DB, Patel DD. **(1996)** Electrophoretic pattern of serum glycoprotein on polyacrylamide gel in patients with breast cancer. *Anticancer Research*. 16:2089-2094.

Patel PS, Raval GN, Rawal RM, Patel MM, Balar DB, Patel DD. **(1997a)** Importance of glycoproteins in human cancer. *Indian Journal of Biochemistry & Biophysics*. 34:226-233.

Patel PS, Rawal RM, Raval GN, Patel BP, Patel YV, Shah SG et al. **(1997b)** Glycoprotein electrophoretic pattern in sera of patients with oral precancerous conditions and upper aerodigestive tract cancer. *J. Exp. Clin. Cancer Res*. 16(1):65-70.

Patel PS, Telang SD, Rawal RM, Shah MH. **(2005b)** Mini review-A Review of proteomics in cancer research. *Asian Pacific J Cancer Prev*. 6:113-117.

Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. **(2004)** Clinical proteomics: Translating benchside promise into bedside reality. *Nature*. 20-32.

Philippe E, Van den Steen, Benedicte Dubois, et al. **(2002)** Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9). *Critical Reviews in Biochemistry and Molecular Biology*. 37(6):375-536.

Puthier D, Derenne S, Barille S et al. **(1999)** Mcl-1 and Bcl-xL are co regulated by IL-6 in human myeloma cells. *Br. J. Haematol*. 107:392-395.

Rajpura KB, Patel PS, Chawda JG, Shah RM. **(2005)** Clinical significance of total and lipid bound sialic acid levels in oral pre-cancerous conditions and oral cancer. *J Oral Pathol Med*. May; 34(5):263-267.

Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffe E, Ines Puricelli L. **(2002)** Circulating 92-kilodalton matrix metalloproteinase (MMP-9)

activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. *Cancer*. 94: 1483–1491.

Rauvala M, Puistola U, Turpeenniemi-Hujanen T. (2005) Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. *Gynecologic Oncology*. December; 99(3) 656-663.

Raval GN, Patel DD, Parekh LJ, Patel JB, Shah MH, Patel PS. (2003) Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. *Oral Disease*. 9: 119-128.

Rawal RM, Parikh BJ, Patel JB, Shah PM, Patel PS. (2003) Monoclonal gammopathies in multiple myeloma: An institutional experience. *GCRI Bulletin*. Vol (8) May. 26-34.

Rawal RM, Patel PS, Patel BP, Raval GN, Patel MM, Bhatavdekar JM, Dixit SA, Patel DD. (1999) Evaluation of glycoprotein constituents in head and neck cancer patients undergoing radiotherapy. *Head Neck*. May; 21(3):192-197.

Reynolds T. (2002) For proteomics research, a new race has begun. *J.Natl.Cancer.Inst.* 94:552-554.

Rhee JS, Diaz R, Kortess L, Hodgson JG, Coussens LM. (2004) TIMP-1 alters susceptibility to carcinogenesis. *Cancer Research*. 64: 952-961.

Richardson PG, Anderson KC. (2004) Remedica publisher. Multiple Myeloma. 1- 26.

Ries C, Pitsch T, Mentele R et al. (2007) Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-) catalytic activation and resistance to inhibition by TIMP-1. *Biochem. J.* 405: 547–558.

Rocca LG, Pucci Minafra I, Marrazzo A, Taormina P, Minafra S. (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer Sera. *British J Cancer*. 90(7)1414-1421.

Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA jr, Kallakury BV. (2003) Prognostic significance of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in prostate cancer. *Mod-Pathol*. 3:198-205.

Roy A, Chakraborty S. (2005) Detection of cancer cervix by estimation of sialic acid. *J Indian Med Assoc*. 103(11):589-590.

Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. (2001) Glycosylation and the immune system. *Science*. 291: 170-176.

Ryu JW, Kim HJ, Lee YS, Myong NH, Hwang CH, Lee GS, Yom HC. (2003) The proteomic approach to find biomarkers in gastric cancer. *J. Korean. Med Sci*. 18: 505-509.

Saito M, Kimoto M, Arakib T, Shimada Y, Ryoji F, Oofusa K et al. (2005) Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers. *European Urology*. Nov 48(5): 865-871.

Sakata K, Shigemasa K, Nagai N, Ohama K. (2000) Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. *Int J Oncol*. 17: 673-681.

Salmon SE, Cassady JR. (1993) Cancer of the breast. In: Cancer: principles and practice of oncology. (De Vita VT Jr, Hellman S and Rosenberg SA eds). Philadelphia, Pennsylvania. 1984-2025.

Sambrook J, Russell DW (2001) (3rd edition) edited by Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Molecular Cloning: A Laboratory Manual. pp SDS-PAGE of proteins. A8.40-A8.49.

Samson D. (2000) Congress report on paraproteinaemias: pathophysiology. *Schweiz Med Wochenschr*. 130:1643-1648.

Sebzda T, Saleh Y, Gburek J, Warwas M, Andrzejak R. (2006) Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage. *J Exp Ther Oncol*. 5(3):223-229.

Shah MH, Telang SD, Shah PM, Patel PS. (2008) Tissue and serum α 2-3 and α 2-6 linkage specific sialylation changes in oral carcinogenesis. *Glycoconjugate J*. 25: 279-290.

Shain KH, Landowski TH, Dalton WS. (2000) The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. *Curr Opin Oncol*. 12:557-563.

Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. (2001) Serum levels of matrix metalloproteinase 2 in patients with breast cancer. *Cancer Lett*. 173: 79-82.

Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, Hsu SM. (2003) Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. *Cancer Research*. October 1; 63: 6537-6542.

Shevchenko A, Wilm M, Vorm O, Mann M. (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. *Anal. Chem*. 68: 850-858.

Simi L, Andreani M, Davini F, Janni A, Pazzagli M, Serio M, Orlando C. (2004) Simultaneous measurement of MMP-9 and TIMP-1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. *Lung cancer*. 45(2):171-179.

Sis B, Sagol O, Kupelioglu A et al. (2004) Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. *Pathol Res Pract*. 200: 379-387.

Skoza L, Mohos S. (1976) The thiobarbituric acid assay of sialic acid. *Biochem J*. 159: 457-462.

Sliwowska I, Kopczynski Z. (2007) Zymography-method for quantitation on gelatinase A (pro-MMP-2, 72 KDa) and gelatinase B (pro-MMP-9, 92 KDa) in serum of patients with breast cancer. *Wiad Lek*. 60 (5-6):241-247.

Snoek-van Beurden PAM and Von den Hoff JW. (2005) Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. *Biotechniques*. 38:73-83.

Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI. (2006) Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of Developing breast cancer. *Cancer Lett*. 233: 98-107.

Srinivas PR, Srivastava S, Hanash S, Wright GL. (2001) Proteomics in early detection of cancer. *Clinical Chemistry*. 47(10): 1901-1911.

Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. (2006) Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. *BMC Urol*. 6: 19.

Stankovic S, Konjevic G, Jelic S, Inic M, Gopcevic K. (2006) Activity levels of MMP-2 and MMP-9 and their complexes with TIMPs in the sera of breast cancer patients [abstract]. 19th Meeting of the European Association for Cancer Research; Budapest, Hungary; 2006. p. 194.

Townson JL, Chambers AF. (2006) Dormancy of solitary metastatic cells. *Cell Cycle*. 5(16):1744-1750.

Traving C, Schauer R. (1998) Review- Structure, function and metabolism of sialic acid. *CMLS. Cell. Mol. Life. Sci*. 54:1330-1349.

Turpeenniemi-Hujanen T. (2005) Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. *Biochimie*. 87: 287-297.

Unger ER, Steinau M, Rajeevan MS, Swan D, Lee DR, Vernon SD. (2004) Molecular markers for early detection of cervical neoplasia. *Disease Marker*. 20: 103-116.

Urashima M, Teoh G, Ogata A et al. (1997) Characterization of p16 (INK4A) expression in multiple myeloma and plasma cell leukemia. *Clin Cancer Research*. 3:2173-2179.

Uslu C, Taysi S, Akcay F, Sutbeyaz MY, Bakan N. (2003) Serum free and bound sialic acid and alpha-1-acid glycoprotein in patients with laryngeal cancer. *Ann Clin Lab Sci*. Spring; 33(2):156-159.

Vacca A, Moretti S, Ribatti D, Pellegrino A, Pimpinell N, Bianchi B, Bonifazi E, Ria R, Serio G, Dammacco F. **(1997)** Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. *Eur J Cancer*. 33: 1685-1692.

Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. **(1999)** Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. *Blood*. (May 1) 93(9): 3064-3073.

Vacca A, Ribatti D, Ria R, Pellegrino A, Bruno M, Merchionne F, Dammacco F. **(2000)** Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. *Dev Immunol*. 7: 77-88.

Van den Steen PE, Dubois B., Nelissen I et al. **(2002)** Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). *Crit Rev Biochem Mol Biol*. 37: 375-536.

Vilos GA, **(1998)** The history of the Papanicolaou smear and the odyssey of George and Andromache Papanicolaou. *Obstet Gynecol*. 91(3): 479-83.

Wang PH. **(2006)** Altered sialylation and its roles in gynecologic cancers. *Journal of Cancer Molecules*. 2(3):107-116.

Washburn MP, Koller A, Oshiro G et al. **(2003)** Protein pathway and complex clustering of correlated mRNA and protein expression analyses in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA*. Mar 18; 100(6):3107-3112.

Wass ET, Hendriks T, Lomme R-MLM, Wobbes T. **(2005)** Plasma levels of matrix metalloproteinase -2 and tissue inhibitor of matrix metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. *Dis Colon Rectum*. 48(4):700-710.

Wass ET, Lomme R-MLM, DeGroot J, Wobbes T, Hendriks T. **(2002)** Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. *Br. J. Cancer*. 86(12):1876-1883.

Wass ET, Wobbes T, Lomme RM, DeGroot J, Ruers T, Hendriks T. **(2003)** Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. *Br. J. Surg*. 90(12):1556-1564.

Wass ET, Wobbes Th, Ruers T, Lomme RMLM, Hendriks T. **(2006)** Circulating gelatinases and tissue inhibitors of metalloproteinase 1 in colorectal cancer metastasis liver disease. *EJSO*. 32:756-763.

Westermeier R and Naven T. **(2002)** Proteomics in practice-A laboratory manual of proteome analysis. Wiley-VCH publisher:1-311.

Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF et al. **(1996a)** Progress with proteome projects. Why all

proteins expressed by a genome should be identified and how to do it. *Biotechnol Genet Eng Rev.* 13:19-50.

Wilkins MR, Sanchez JC, Williams KL, Hochstrasser DF. **(1996b)** Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. *Electrophoresis.* 17:830-838.

Winzler RJ. **(1955)** (2nd ed) Vol.II. Determination of serum glycoproteins. In: Glick D (ed), *Methods of Biochemical Analysis*. New York, Intersciences Publishers.279-311.

Woessner FJ and Nagase H. **(2000)** *Matrix metalloproteinases and TIMPs* (New York, USA:Oxford University Press).

Woessner FJ, Nagase H. **(2002)** (Oxford university press) *Matrix metalloproteinases and TIMPs*; New York. 1-221.

Wongkham S, Bhudhisawasdi V, Chau-in S, Boonla C, Muisuk K, Kongkham S, Wongkham C, Boonsiri P, Thuwajit P. **(2003)** Clinical significance of serum total sialic acid in cholangiocarcinoma. *Clin Chim Acta.* Jan; 327(1-2):139-147.

Wootton IDP. **(1964)** (ed) *Plasma proteins*. In: Wootton IDP, *Micro-analysis in Medical Biochemistry*. London: J & A Churchill Ltd. 138-153.

Wu W, Hu W, Kavanagh JJ. **(2002)** Proteomics in cancer research. *J Gynecol Cancer.*12: 409-423.

Xing RD, Wang ZS, Li CQ, Tang QY, Jiang CB, Zhang YZ. **(1994)** Total sialic acid as a tumor marker for oral cancer. *Int. J. Biol Markers.* 9:239-242.

Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. **(2000)** Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer-TIMP-1 as a prognostic marker.*Anticancer Res.* 20: 1311–1316.

Yu Bo, Li SH, An P, Zhang YN, Liang ZJ, Yuan SJ, Yun Cai H. **(2004)** Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer. *World Journal of Gastroenterology.* 10(18):2652-2656.

Zhang LY, Ying WT, Mao YS, He HZ, Liu Y, Wang HX, Liu F, Wang K, Zhang DC, Wang Y, Wu M, Qian XH, Zhao XH. **(2003)** Loss of clustrin both in serum and tissue correlated with the tumorigenesis of esophageal squamous cell carcinoma via proteomic approachs. *World Journal of Gastroenterology.* 9(4):650-654.

Zivaljevic B, Vlajinac H, Adanja B, Zivaljevic V, Kocev N. **(2001)** Smoking as risk factor for cervical cancer.*Neoplasma.*48(4):254-256.